drugset / Trial / NCT00033202
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
Phase 1
Completed
30 enrolled
Sigma-Tau Research, Inc.
Dana-Farber Cancer Institute · collabRhode Island Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.
Timeline
- Start
- 2002-03
- Primary completion
- —
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gimatecan | Small molecule | — | Oral |